AARTI PHARMALABS
|
AARTI PHARMALABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 23.93 | 21.35 | 4,890.04 | -0.18 |
| CEPS(Rs) | 32.01 | 28.25 | 6,574.79 | -0.18 |
| DPS(Rs) | 3.00 | 2.00 | - | - |
| Book NAV/Share(Rs) | 193.85 | 171.97 | 53,646.60 | 9.12 |
| Tax Rate(%) | 27.82 | 25.80 | 21.32 | - |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 20.84 | 17.58 | 17.11 | - |
| EBIT Margin(%) | 17.15 | 14.49 | 13.95 | - |
| Pre Tax Margin(%) | 16.22 | 13.41 | 12.95 | - |
| PAT Margin (%) | 11.71 | 9.95 | 10.19 | - |
| Cash Profit Margin (%) | 15.66 | 13.16 | 13.70 | - |
| Performance Ratios | ||||
| ROA(%) | 8.99 | 9.03 | 11.98 | -1.84 |
| ROE(%) | 13.08 | 13.35 | 18.23 | -2.02 |
| ROCE(%) | 16.75 | 16.11 | 19.40 | -1.87 |
| Asset Turnover(x) | 0.77 | 0.91 | 1.18 | - |
| Sales/Fixed Asset(x) | 1.22 | 1.46 | 0.98 | - |
| Working Capital/Sales(x) | 2.84 | 3.46 | 2.68 | - |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.82 | 0.68 | 1.02 | - |
| Receivable days | 95.50 | 77.57 | 114.57 | - |
| Inventory Days | 122.63 | 101.09 | 144.62 | - |
| Payable days | 128.34 | 86.45 | 61.41 | - |
| Valuation Parameters | ||||
| PER(x) | 18.18 | 12.86 | - | - |
| PCE(x) | 13.59 | 9.72 | - | - |
| Price/Book(x) | 2.24 | 1.60 | - | - |
| Yield(%) | 0.69 | 0.73 | - | - |
| EV/Net Sales(x) | 2.26 | 1.38 | 0.21 | - |
| EV/Core EBITDA(x) | 10.70 | 7.81 | 1.22 | -3.76 |
| EV/EBIT(x) | 13.16 | 9.55 | 1.53 | -3.76 |
| EV/CE(x) | 2.07 | 1.52 | 0.15 | 0.07 |
| M Cap / Sales | 2.13 | 1.28 | - | - |
| Growth Ratio | ||||
| Net Sales Growth(%) | -4.76 | 62.11 | - | - |
| Core EBITDA Growth(%) | 13.52 | 64.41 | - | - |
| EBIT Growth(%) | 12.73 | 68.42 | - | - |
| PAT Growth(%) | 12.10 | 58.28 | - | - |
| EPS Growth(%) | 12.10 | -99.56 | - | - |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.15 | 0.14 | 0.25 | 0.08 |
| Current Ratio(x) | 1.94 | 1.94 | 1.77 | 11.42 |
| Quick Ratio(x) | 1.01 | 0.93 | 0.95 | 11.42 |
| Interest Cover(x) | 18.46 | 13.39 | 13.99 | - |
| Total Debt/Mcap(x) | 0.07 | 0.09 | - | - |
Compare Financial Ratios of peers of AARTI PHARMALABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AARTI PHARMALABS | ₹5,749.0 Cr | -3% | 4% | 63.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹426,518.0 Cr | -1.4% | -7.1% | 48% | Stock Analytics | |
| DIVIS LABORATORIES | ₹158,636.0 Cr | 1.5% | -2.1% | 63% | Stock Analytics | |
| CIPLA | ₹118,368.0 Cr | -3.5% | -5.2% | 18% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,671.4 Cr | -3.9% | -10.1% | 10.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,013.6 Cr | -0.3% | -7.3% | 52.2% | Stock Analytics | |
AARTI PHARMALABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AARTI PHARMALABS | -3% |
4% |
63.3% |
| SENSEX | -2.4% |
-4.2% |
19.5% |
You may also like the below Video Courses
